Conatus Pharmaceuticals Inc (CNAT) 6.31 $CNAT Nasdaq

New Post Public Reply Private Reply Replies (0) Message Board

Apr 23, 2015 at 1:33 AM

Conatus Pharmaceuticals Inc (CNAT) 6.31 $CNAT

Nasdaq stocks posting largest percentage increases
AP - Thu Apr 16, 12:29PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HTBX: 7.71 (-0.64), NFLX: 557.68 (-2.76), SAGE: 59.50 (-2.56), ARCW: 7.06 (-0.57), TZOO: 13.06 (-0.02), GLMD: 10.00 (-0.12), LAYN: 5.58 (+0.28), CNAT: 6.31 (-0.15), ANGI: 6.46 (+0.31), VLTC: 15.14 (-1.04), MNTA: 18.62 (+0.56), AREX: 8.15 (-0.30)

Fatty Liver Disease Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Thu Apr 16, 10:30AM CDT
The report "Fatty Liver Disease - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Fatty Liver Disease. Fatty liver disease is characterized by increased accumulation of fat, especially triglycerides, in the liver cells. Many people with fatty liver disease experience no symptoms, especially in the early stage of the disease. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/fatty-liver-...eport.html .
RPTP: 10.56 (-0.17), GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), CCXI: 7.86 (-0.02), DRRX: 2.19 (+0.10), TBRA: (), NVS: 103.45 (-0.62)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 4:36PM CDT

FIS: 64.28 (+0.19), BAK: 8.04 (+0.21), STV: 4.00 (+0.19), CNAT: 6.31 (-0.15), KTEC: 13.00 (+0.13), KOS: 8.48 (-0.02), TOWR: 26.94 (+0.32), GCA: 7.74 (+0.17), EXTR: 2.52 (-0.01), XOMA: 3.63 (-0.04)

Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Wed Apr 08, 3:01PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today the completion of its previously announced underwritten public offering of 4,025,000 shares of its common stock, including 525,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. All shares in the offering were sold by Conatus at a price to the public of $5.75 per share. Net proceeds to Conatus from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $21.4 million.
CNAT: 6.31 (-0.15)

UPDATE -- Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting
GlobeNewswire - Wed Apr 08, 8:14AM CDT
In a release issued earlier this morning by Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), two subheadings were missing from the text. The subheadings have been added and the updated release follows in its entirety.
CNAT: 6.31 (-0.15)

Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting
GlobeNewswire - Wed Apr 08, 6:01AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today that three posters addressing clinical results with emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, have been accepted for presentation at The International Liver Congress(TM) 2015, the 50 Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 22-26, 2015.
CNAT: 6.31 (-0.15)

Regulus Soars As AstraZeneca Grabs NASH Drug Rights
at Investor's Business Daily - Tue Apr 07, 6:41PM CDT
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making...
GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ICPT: 280.45 (-8.26), ABBV: 64.52 (+0.91), RGLS: 17.40 (-0.22)

Conatus to Present at Needham Healthcare Conference
GlobeNewswire - Tue Apr 07, 6:10AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today its scheduled presentation of the company's programs and outlook at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015, at 2:20 p.m. ET, in New York. A copy of the presentation will be available in the Investor Center of the company's website at www.conatuspharma.com.
CNAT: 6.31 (-0.15)

Conatus prices public offering at USD5.75 per share
M2 - Fri Apr 03, 6:18AM CDT
Biotechnology company Conatus Pharmaceuticals (NasdaqGM:CNAT) disclosed on Thursday that it has priced its public offering of 3,500,000 shares of its common stock at a price of USD5.75 per share.
CNAT: 6.31 (-0.15)

Conatus Pharmaceuticals (CNAT) Stock Falls Today After Pricing Public Offering
at The Street - Thu Apr 02, 1:07PM CDT
Shares of Conatus Pharmaceuticals (CNAT) were down in afternoon trading Thursday after the company priced an underwritten public offering of its common stock.
CNAT: 6.31 (-0.15)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 11:45AM CDT

KRNT: 14.99 (unch), ARCW: 7.06 (-0.57), TOF: 4.12 (-0.03), SSN: 1.54 (-0.02), CNAT: 6.31 (-0.15), NYMX: 1.32 (-0.08), SEAC: 7.23 (+0.25), UACL: 22.34 (+0.42), WBAI: 16.75 (-0.46), LBIX: 3.60 (+0.22), CARB: 11.14 (-0.07), EBIO: 10.32 (+0.22), CTSO: 7.13 (-0.06), AKER: 4.55 (+0.05), SQBG: 13.46 (-0.54), TRIB: 17.17 (-0.17), OCRX: 3.86 (-0.07), TCPI: 3.85 (-0.13), TRUE: 15.72 (-0.26), FHCO: 3.19 (+0.02)

Conatus prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 10:20AM CDT

CNAT: 6.31 (-0.15)

The Zacks Analyst Blog Highlights: Horizon Pharma, Hyperion Therapeutics, Conatus, Amgen and Biogen - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Horizon Pharma, Hyperion Therapeutics, Conatus, Amgen and Biogen
BIIB: 423.57 (+1.46), CNAT: 6.31 (-0.15), HZNP: 30.96 (+0.10), AMGN: 169.10 (+0.64), HPTX: 45.96 (-0.18)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 8:13AM CDT

KMX: 70.84 (-0.04), CARB: 11.14 (-0.07), TXMD: 7.17 (+0.01), CERU: 5.99 (-0.20), CNAT: 6.31 (-0.15), RPRX: 8.36 (-0.15), LBIO: 12.50 (+0.50), FXCM: 2.13 (+0.02), CAPN: 6.99 (-0.29), WBAI: 16.75 (-0.46)

Conatus Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Apr 02, 8:00AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it has priced an underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $5.75 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be approximately $20.1 million.
CNAT: 6.31 (-0.15)

Conatus initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 3:14PM CDT

CNAT: 6.31 (-0.15)

Conatus Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Apr 01, 3:01PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Conatus also expects to grant to the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Conatus. Conatus intends to use the net proceeds from the offering to fund clinical development of emricasan, including preparation for registration trials, and for working capital and other general corporate purposes.
CNAT: 6.31 (-0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Data Center Piping Surges With AI Cooling to $4.5B

Liquid Cooling Revolutionizes Data Center Infrastructure Gotta hand it to the tech world, when it decides to shift, it shifts hard and fast. The data center piping market isn't just keeping up—it's sprinting. The move towards liquid-cooled AI setups isn’t just a trend; it’s a defining transformation. With a projected explosion to a $4.5 billion market by 2035, you...

AI Campuses Drive Surge in Power Cable Market

Surge in Data Center Power Cable Demand Walking down the old data center aisle, you'd never imagine so much copper snaking its way into the modern megalith of AI campuses. But here we are, staring at a market projected to leap from USD 1.74 billion in 2025 to a whopping USD 4.72 billion by 2035. That's a compounded annual growth rate (CAGR) of a robust 10.50%, and it’s...

Rocket Companies' Earnings Preview: What's at Stake?

Anticipation Builds Around Rocket's Earnings Call It ain't every day that a company's earnings announcement stirs up interest the way Rocket Companies' (NYSE:RKT) upcoming third-quarter results have. But here we are, just days away from October 29, 2026, when leadership will lay out the cards at 4:30 p.m. ET. This announcement might just be what investors like us need to...

AMTD Digital's Half-Year Results Stir Investor Interest

AMTD Digital Warming Up for a Busy Quarter Some things just catch the wind differently in the market, and when a heavyweight like AMTD Digital starts talking numbers, everybody perks up. They're gearing up to drop their half-year financials, ready to roll out at the stroke of midnight on October 23rd, and investor ears across the globe are pricked for what’s coming down...

Vertice P2P Aims to Transform Procurement Efficiency

Vertice Dives Deeper into the Procurement Game Grab a coffee and let's talk some procurement—one of the least sexy, yet utterly essential parts of any operation. Vertice's latest announcement is anything but mundane. They're spiraling deeper into the procurement universe with their new Procure-to-Pay (P2P) capability, a bold expansion from their Intake-to-Procure (I2P)...

Lunai Bioworks Voluntarily Delists After Equity Snags

Bracing for the Delisting Impact Well, isn't that a familiar tune? Lunai Bioworks Inc., ticking with the symbol NASDAQ:LNAI, is pulling the plug on its Nasdaq listing faster than a kid yanking out a loose tooth. On October 21, 2026, the company's board decided it's cheaper and simpler to step off the dance floor than keep paying for a spot when the music's stopped....

Centrus Energy to Discuss Q3 Earnings on Nov 5 Call

Centrus Energy Prepares for Earnings Call You ever feel that twinge in your gut right before a big disclosure? Well, that's where Centrus Energy’s about to take us as they gear up for their quarterly earnings call. On November 5th, bright and early at 8:30 a.m. Eastern Time, NYSE:LEU will be in the spotlight, laying out its Q3 results for all us nose-to-the-grindstone...

Venture Dock Fosters Global Startup Ecosystems

Venture Dock Connects the Global Startup Dots When it comes down to bridging the gap between promising innovation and commercial success, you'd be hard-pressed to find a better player than Venture Dock. In a world filled with buzzwords and fluff, these guys are socketed deep in the guts of genuine startup development — and they're making waves with their recent...

Beggin' Unveils Festive Treats for Canine Thanksgiving

Dog Treats That Spice Up Thanksgiving Feast Just when you thought Thanksgiving was all about the humans crowding around a table of turkey and stuffing, Beggin' decides to throw the dogs a bone—literally. These guys rolled out their limited-edition holiday treats that’ll probably have your pup sniffin’ the air like it’s the early days of autumn. What's Cookin' In...

PENNVEST Grants $42M for PA Water Upgrades

Big Boost for Pennsylvania's Water Infrastructure The recent announcement about Pennsylvania American Water scoring a $42 million package from PENNVEST feels like a solid win for everyone except complacency. This move is a direct nod to infrastructure sorely needing an upgrade in Lackawanna and Montgomery counties. You'd think these improvements were long overdue with all...